Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review
Clin Colorectal Cancer. 2024 Feb 21:S1533-0028(24)00005-7. doi: 10.1016/j.clcc.2024.01.005. Online ahead of print.NO ABSTRACTPMID:38519390 | DOI:10.1016/j.clcc.2024.01.005 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Dorien Geusens Daan Dierickx Saskia Carton Eric Van Cutsem Jeroen Dekervel Source Type: research
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
Clin Colorectal Cancer. 2024 Feb 16:S1533-0028(24)00006-9. doi: 10.1016/j.clcc.2024.02.001. Online ahead of print.ABSTRACTLiquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metas...
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Laura Roazzi Giorgio Patelli Katia Bruna Bencardino Alessio Amatu Erica Bonazzina Federica Tosi Brunella Amoruso Anna Bombelli Sara Mariano Stefano Stabile Camillo Porta Salvatore Siena Andrea Sartore-Bianchi Source Type: research
Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities
Clin Gastroenterol Hepatol. 2024 Apr;22(4):679-683. doi: 10.1016/j.cgh.2024.01.001.NO ABSTRACTPMID:38519261 | DOI:10.1016/j.cgh.2024.01.001 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Ishani Shah Andrew J Gawron Kathryn R Byrne John M Inadomi Source Type: research
Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review
Clin Colorectal Cancer. 2024 Feb 21:S1533-0028(24)00005-7. doi: 10.1016/j.clcc.2024.01.005. Online ahead of print.NO ABSTRACTPMID:38519390 | DOI:10.1016/j.clcc.2024.01.005 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Dorien Geusens Daan Dierickx Saskia Carton Eric Van Cutsem Jeroen Dekervel Source Type: research
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
Clin Colorectal Cancer. 2024 Feb 16:S1533-0028(24)00006-9. doi: 10.1016/j.clcc.2024.02.001. Online ahead of print.ABSTRACTLiquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metas...
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Laura Roazzi Giorgio Patelli Katia Bruna Bencardino Alessio Amatu Erica Bonazzina Federica Tosi Brunella Amoruso Anna Bombelli Sara Mariano Stefano Stabile Camillo Porta Salvatore Siena Andrea Sartore-Bianchi Source Type: research
Serrated adenocarcinoma of sigmoid colon with mismatch repair protein-proficient phenotype: Histopathological recognition of a new subtype of colorectal adenocarcinoma
Clin Case Rep. 2024 Mar 19;12(3):e8669. doi: 10.1002/ccr3.8669. eCollection 2024 Mar.ABSTRACTSerrated adenocarcinoma is a distinct subtype of colorectal carcinoma characterized by unique histological and molecular features. Here we present a case study of a 58-year-old female patient who presented with generalized weakness, abdominal discomfort, and per-rectal bleeding. This case report highlights the importance of understanding the histopathological features of serrated adenocarcinoma for accurate diagnosis which has impact on further management.PMID:38510231 | PMC:PMC10950788 | DOI:10.1002/ccr3.8669 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Diksha Karki Sajan Ngakhusi Source Type: research
Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: a Review of Evidence
Clin Med Insights Oncol. 2024 Mar 19;18:11795549241236409. doi: 10.1177/11795549241236409. eCollection 2024.ABSTRACTThe treatment of locally advanced rectal cancer (LARC) is a challenging situation for radiation oncologists and colorectal surgeons. Most current approaches recommend neoadjuvant fluorouracil or capecitabine-based chemoradiotherapy followed by surgery as a standard of care. Intensification of concurrent chemotherapy by adding oxaliplatin to fluorouracil or capecitabine backbone to get better outcomes is the matter that has remained unresolved. In this review, we searched Medline and Google Scholar databases a...
Source: Clinical Colorectal Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Reza Nazari Guglielmo Niccol ò Piozzi Reza Ghalehtaki Seyed Mohsen Ahmadi-Tafti Behnam Behboudi Nima Mousavi Darzikolaee Mahdi Aghili Maria Antonietta Gambacorta Source Type: research
Serrated adenocarcinoma of sigmoid colon with mismatch repair protein-proficient phenotype: Histopathological recognition of a new subtype of colorectal adenocarcinoma
Clin Case Rep. 2024 Mar 19;12(3):e8669. doi: 10.1002/ccr3.8669. eCollection 2024 Mar.ABSTRACTSerrated adenocarcinoma is a distinct subtype of colorectal carcinoma characterized by unique histological and molecular features. Here we present a case study of a 58-year-old female patient who presented with generalized weakness, abdominal discomfort, and per-rectal bleeding. This case report highlights the importance of understanding the histopathological features of serrated adenocarcinoma for accurate diagnosis which has impact on further management.PMID:38510231 | PMC:PMC10950788 | DOI:10.1002/ccr3.8669 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Diksha Karki Sajan Ngakhusi Source Type: research
Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: a Review of Evidence
Clin Med Insights Oncol. 2024 Mar 19;18:11795549241236409. doi: 10.1177/11795549241236409. eCollection 2024.ABSTRACTThe treatment of locally advanced rectal cancer (LARC) is a challenging situation for radiation oncologists and colorectal surgeons. Most current approaches recommend neoadjuvant fluorouracil or capecitabine-based chemoradiotherapy followed by surgery as a standard of care. Intensification of concurrent chemotherapy by adding oxaliplatin to fluorouracil or capecitabine backbone to get better outcomes is the matter that has remained unresolved. In this review, we searched Medline and Google Scholar databases a...
Source: Clinical Colorectal Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Reza Nazari Guglielmo Niccol ò Piozzi Reza Ghalehtaki Seyed Mohsen Ahmadi-Tafti Behnam Behboudi Nima Mousavi Darzikolaee Mahdi Aghili Maria Antonietta Gambacorta Source Type: research
Specific deletion of Mettl3 in IECs triggers the development of spontaneous colitis and dysbiosis of T lymphocytes in mice
Clin Exp Immunol. 2024 Mar 20:uxae025. doi: 10.1093/cei/uxae025. Online ahead of print.ABSTRACTThe enzymatic core component of m6A writer complex, Mettl3, plays a crucial role in facilitating the development and progress in gastric and colorectal cancer (CRC). However, its underlying mechanism in regulating intestinal inflammation remains unclear and poorly investigated. Firstly, the characteristics of Mettl3 expression in IBD patients were examined. Afterwards we generated the mice line with IECs-specific deletion of Mettl3 verified by various experiments. We continuously recorded and compared the physiological status inc...
Source: Clinical Colorectal Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Miao Fang Jie Yao Haifeng Zhang Jiahui Sun Yiping Yin Hongzhou Shi Guangqing Jiang Xin Shi Source Type: research
microRNAs, oxidative stress, and genotoxicity as the main inducers in the pathobiology of cancer development
Horm Mol Biol Clin Investig. 2024 Mar 21. doi: 10.1515/hmbci-2023-0012. Online ahead of print.ABSTRACTCancer is one of the most serious leading causes of death in the world. Many eclectic factors are involved in cancer progression including genetic and epigenetic alongside environmental ones. In this account, the performance and fluctuations of microRNAs are significant in cancer diagnosis and treatment, particularly as diagnostic biomarkers in oncology. So, microRNAs manage and control the gene expression after transcription by mRNA degradation, or also they can inhibit their translation. Conspicuously, these molecular st...
Source: Clinical Colorectal Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Sogand Vahidi Shahram Agah Ebrahim Mirzajani Elahe Asghari Gharakhyli Seyedeh Elham Norollahi Morteza Rahbar Taramsari Kosar Babaei Ali Akbar Samadani Source Type: research
Xevinapant combined with pembrolizumab in patients with advanced, pretreated colorectal and pancreatic cancer: results of the phase 1b/2 CATRIPCA trial
CONCLUSIONS: Xevinapant combined with pembrolizumab was well tolerated with no unexpected adverse events. However, anti-tumor activity was low.PMID:38502104 | DOI:10.1158/1078-0432.CCR-23-2893 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Allison Voisin Catherine Terret Camille Schiffler Anne-Sophie Bidaux H élène Vanacker Marl ène Perrin-Niquet Maud Barbery Armelle Vinceneux Lauriane Eberst Pierre Stephan Gwenaele Garin Dany Spaggiari David P érol Yenkel Grinberg-Bleyer Philippe A Cas Source Type: research
Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer
CONCLUSIONS: Our genomic analysis suggests that high baseline CIN or effective induction of enhanced mutagenesis on targeted therapy underlies rapid progression. Longer response appears to result from a progressive acquisition of genomic or chromosomal instability in the underlying cancer or from the chance event of a new resistance alteration.PMID:38502113 | DOI:10.1158/1078-0432.CCR-23-4005 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Emily Harrold Fergus Keane Henry Walch Joanne F Chou Jenna Sinopoli Silvia Palladino Duaa H Al-Rawi Kalyani Chadalavada Paolo Manca Sree Chalasani Jessica Yang Andrea Cercek Jinru Shia Marinela Capanu Samuel F Bakhoum Nikolaus Schultz Walid K Chatila Rona Source Type: research
Xevinapant combined with pembrolizumab in patients with advanced, pretreated colorectal and pancreatic cancer: results of the phase 1b/2 CATRIPCA trial
CONCLUSIONS: Xevinapant combined with pembrolizumab was well tolerated with no unexpected adverse events. However, anti-tumor activity was low.PMID:38502104 | DOI:10.1158/1078-0432.CCR-23-2893 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Allison Voisin Catherine Terret Camille Schiffler Anne-Sophie Bidaux H élène Vanacker Marl ène Perrin-Niquet Maud Barbery Armelle Vinceneux Lauriane Eberst Pierre Stephan Gwenaele Garin Dany Spaggiari David P érol Yenkel Grinberg-Bleyer Philippe A Cas Source Type: research
Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer
CONCLUSIONS: Our genomic analysis suggests that high baseline CIN or effective induction of enhanced mutagenesis on targeted therapy underlies rapid progression. Longer response appears to result from a progressive acquisition of genomic or chromosomal instability in the underlying cancer or from the chance event of a new resistance alteration.PMID:38502113 | DOI:10.1158/1078-0432.CCR-23-4005 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Emily Harrold Fergus Keane Henry Walch Joanne F Chou Jenna Sinopoli Silvia Palladino Duaa H Al-Rawi Kalyani Chadalavada Paolo Manca Sree Chalasani Jessica Yang Andrea Cercek Jinru Shia Marinela Capanu Samuel F Bakhoum Nikolaus Schultz Walid K Chatila Rona Source Type: research
